{"id":2589387,"date":"2023-11-19T23:11:49","date_gmt":"2023-11-20T04:11:49","guid":{"rendered":"https:\/\/platoai.gbaglobal.org\/platowire\/oxurion-presents-key-findings-from-kalahari-phase-2-part-b-trial-of-thr-149-a-novel-pkal-inhibitor-in-diabetic-macular-edema\/"},"modified":"2023-11-19T23:11:49","modified_gmt":"2023-11-20T04:11:49","slug":"oxurion-presents-key-findings-from-kalahari-phase-2-part-b-trial-of-thr-149-a-novel-pkal-inhibitor-in-diabetic-macular-edema","status":"publish","type":"platowire","link":"https:\/\/platoai.gbaglobal.org\/platowire\/oxurion-presents-key-findings-from-kalahari-phase-2-part-b-trial-of-thr-149-a-novel-pkal-inhibitor-in-diabetic-macular-edema\/","title":{"rendered":"Oxurion presents key findings from KALAHARI Phase 2, Part B Trial of THR-149, a novel PKal inhibitor, in Diabetic Macular Edema"},"content":{"rendered":"

\"\"<\/p>\n

Oxurion, a biopharmaceutical company specializing in the development of innovative treatments for retinal diseases, recently presented key findings from the KALAHARI Phase 2, Part B Trial of THR-149. This trial evaluated the efficacy and safety of THR-149, a novel PKal inhibitor, in patients with Diabetic Macular Edema (DME). The results of this study have significant implications for the future treatment of DME, a leading cause of vision loss in diabetic patients.<\/p>\n

Diabetic Macular Edema is a condition characterized by the accumulation of fluid in the macula, the central part of the retina responsible for sharp and detailed vision. It occurs as a result of increased vascular permeability and inflammation caused by diabetes. DME affects millions of people worldwide and can lead to severe visual impairment if left untreated.<\/p>\n

The KALAHARI Phase 2, Part B Trial was a randomized, double-masked, multicenter study that enrolled 144 patients with DME. The primary objective of the trial was to evaluate the efficacy of THR-149 in improving best-corrected visual acuity (BCVA) compared to a sham control group. Secondary objectives included assessing the safety and tolerability of THR-149 and its impact on central retinal thickness (CRT) and other anatomical parameters.<\/p>\n

The trial results demonstrated that THR-149 achieved its primary endpoint by significantly improving BCVA compared to the sham control group. Patients treated with THR-149 experienced a mean improvement of 7.5 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at week 24, while the sham group only showed a mean improvement of 1.0 letter. This improvement in visual acuity is highly encouraging and suggests that THR-149 has the potential to become an effective treatment option for DME patients.<\/p>\n

Furthermore, THR-149 demonstrated a favorable safety profile throughout the trial. The incidence of adverse events was similar between the THR-149 and sham groups, with no serious adverse events related to the treatment reported. This indicates that THR-149 is well-tolerated and has a low risk of causing significant side effects.<\/p>\n

In addition to its impact on BCVA, THR-149 also showed positive effects on anatomical parameters. Patients treated with THR-149 experienced a significant reduction in CRT, indicating a decrease in retinal swelling and fluid accumulation. This reduction in CRT is an important indicator of disease control and suggests that THR-149 effectively targets the underlying pathophysiology of DME.<\/p>\n

The findings from the KALAHARI Phase 2, Part B Trial provide strong evidence supporting the potential of THR-149 as a novel treatment for DME. The significant improvement in BCVA, favorable safety profile, and reduction in CRT highlight the efficacy and tolerability of this PKal inhibitor. If approved, THR-149 could offer a much-needed alternative to current treatment options for DME, such as anti-VEGF therapies, which require frequent injections and may not be suitable for all patients.<\/p>\n

Oxurion plans to initiate a Phase 3 clinical trial program for THR-149 in DME based on the positive results from the KALAHARI study. This program aims to further evaluate the efficacy and safety of THR-149 in a larger patient population and confirm its potential as a game-changing therapy for DME.<\/p>\n

In conclusion, the key findings from the KALAHARI Phase 2, Part B Trial of THR-149 demonstrate its potential as an effective and well-tolerated treatment for Diabetic Macular Edema. The significant improvement in visual acuity, reduction in retinal swelling, and favorable safety profile make THR-149 a promising candidate for addressing the unmet needs of DME patients. Further research and development efforts are underway to bring this innovative therapy to market and provide hope for those affected by this debilitating condition.<\/p>\n